仙琚制药
(002332)
| 流通市值：91.66亿 | | | 总市值：92.09亿 |
| 流通股本：9.85亿 | | | 总股本：9.89亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,825,580,737.5 | 1,869,227,375.54 | 1,008,198,242.3 | 4,000,693,148.05 |
| 营业收入 | 2,825,580,737.5 | 1,869,227,375.54 | 1,008,198,242.3 | 4,000,693,148.05 |
| 二、营业总成本 | 2,381,807,724.46 | 1,540,784,233.35 | 843,841,353.08 | 3,310,485,780.21 |
| 营业成本 | 1,065,002,042 | 688,613,769.15 | 450,032,933.28 | 1,700,842,559.24 |
| 税金及附加 | 27,667,995.55 | 18,924,065.74 | 6,806,845.23 | 35,214,121.58 |
| 销售费用 | 841,424,817.23 | 547,773,849.8 | 248,285,768.31 | 1,033,752,829.44 |
| 管理费用 | 254,557,160.59 | 164,426,361.26 | 70,687,334 | 309,786,244.07 |
| 研发费用 | 198,415,154.74 | 125,931,193.93 | 70,771,880.3 | 265,172,350.8 |
| 财务费用 | -5,259,445.65 | -4,885,006.53 | -2,743,408.04 | -34,282,324.92 |
| 其中:利息费用 | 3,223,366.44 | 1,636,833.05 | 148,326.07 | 3,132,732.94 |
| 其中:利息收入 | 12,685,528.25 | 9,371,653.97 | 3,645,082.1 | 29,475,160.84 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -12,250,725.16 | -9,616,902.06 | -5,784,141.64 | -8,135,977.92 |
| 资产处置收益 | 46,269,885.05 | 46,212,235.3 | 1,796.42 | 283,085.44 |
| 资产减值损失(新) | -24,217,765.45 | -24,235,367.74 | - | -43,509,998.98 |
| 信用减值损失(新) | -5,846,584.09 | -4,916,682.98 | -4,057,083.2 | -11,445,758.77 |
| 其他收益 | 16,374,580.92 | 11,154,968.28 | 4,099,037.51 | 50,812,521.56 |
| 四、营业利润 | 464,102,404.31 | 347,041,392.99 | 158,616,498.31 | 678,211,239.17 |
| 加:营业外收入 | 226,490.17 | 365,716.9 | 514,956.35 | 28,960,528.04 |
| 减:营业外支出 | 6,978,308.19 | 4,077,889.25 | 1,251,381.66 | 208,844,571.9 |
| 五、利润总额 | 457,350,586.29 | 343,329,220.64 | 157,880,073 | 498,327,195.31 |
| 减:所得税费用 | 61,480,597.74 | 47,232,563.3 | 19,716,284.23 | 98,403,980.63 |
| 六、净利润 | 395,869,988.55 | 296,096,657.34 | 138,163,788.77 | 399,923,214.68 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 395,869,988.55 | 296,096,657.34 | 138,163,788.77 | 399,923,214.68 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 406,684,611.31 | 308,268,256.98 | 143,983,992.29 | 397,178,995.31 |
| 少数股东损益 | -10,814,622.76 | -12,171,599.64 | -5,820,203.52 | 2,744,219.37 |
| 扣除非经常损益后的净利润 | 363,232,546.08 | 266,773,796.21 | 144,146,524.12 | 549,107,163.61 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.41 | 0.31 | 0.15 | 0.4 |
| (二)稀释每股收益 | 0.41 | 0.31 | 0.15 | 0.4 |
| 八、其他综合收益 | 137,744,065.47 | 149,107,625.78 | 46,221,040.19 | -64,136,651.01 |
| 归属于母公司股东的其他综合收益 | 137,744,065.47 | 149,107,625.78 | 46,221,040.19 | -64,136,651.01 |
| 九、综合收益总额 | 533,614,054.02 | 445,204,283.12 | 184,384,828.96 | 335,786,563.67 |
| 归属于母公司股东的综合收益总额 | 544,428,676.78 | 457,375,882.76 | 190,205,032.48 | 333,042,344.3 |
| 归属于少数股东的综合收益总额 | -10,814,622.76 | -12,171,599.64 | -5,820,203.52 | 2,744,219.37 |
| 公告日期 | 2025-10-28 | 2025-08-27 | 2025-04-24 | 2025-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |